Healthcare of Ontario Pension Plan Trust Fund Purchases New Shares in BioCryst Pharmaceuticals, Inc. $BCRX

Healthcare of Ontario Pension Plan Trust Fund purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,227,040 shares of the biotechnology company’s stock, valued at approximately $11,681,000.

A number of other institutional investors have also added to or reduced their stakes in BCRX. Royal Bank of Canada lifted its position in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the period. Cetera Investment Advisers grew its position in shares of BioCryst Pharmaceuticals by 13.8% in the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares during the period. Captrust Financial Advisors increased its stake in shares of BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 1,527 shares in the last quarter. Counterweight Ventures LLC increased its stake in shares of BioCryst Pharmaceuticals by 2.1% in the 4th quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock worth $744,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 2,115 shares during the period. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of analyst reports. JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 target price for the company. Needham & Company LLC lowered their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Cantor Fitzgerald boosted their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.80.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $9.74 on Wednesday. The firm’s 50 day moving average price is $9.25 and its 200-day moving average price is $8.60. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.00 and a 52-week high of $11.22. The company has a market cap of $2.48 billion, a PE ratio of -5.47 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. During the same period last year, the business earned $0.20 EPS. BioCryst Pharmaceuticals’s revenue was up 7.5% on a year-over-year basis. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.